<DOC>
	<DOCNO>NCT00856323</DOCNO>
	<brief_summary>This study seek decrease methamphetamine use concomitant high-risk sexual behavior among methamphetamine-using men sex men ( MSM ) combine biomedical intervention behavioral intervention . The behavioral intervention consist 8-week course contingency management ( CM ) participant reinforce test negative methamphetamine metabolite periodic urine analysis . The biomedical intervention involve 28-day course antiretroviral drug ( Truvada ) administer unanticipated HIV risk exposure ( i.e. , engage either receptive insertive anal sex without condom someone HIV-positive unknown status ) . In combine two intervention , study seek evaluate combine intervention 's effect sexual risk behavior methamphetamine use .</brief_summary>
	<brief_title>Contingency Management Methamphetamine Abstinence HIV Post-Exposure Prophylaxis Men Who Have Sex With Men</brief_title>
	<detailed_description>At baseline , eligible participant underwent informed consent ; complete baseline assessment ; receive rapid HIV testing ; provide specimen syphilis , gonorrhea chlamydia testing ; receive medical examination . Those report high-risk sexual drug exposure episode HIV-positive serostatus-unknown source within precede 72 hour immediately initiated postexposure prophylaxis . All participant receive 4-day `` starter pack '' Truvada initiate case future high-risk exposure HIV . All participant begin voucher-based CM intervention upon study entry . For initial 8 week study conduct , participant present study site three time weekly urine drug screen methamphetamine metabolite . Participants provide urine sample negative methamphetamine metabolite earn voucher , escalate value successive negative urine sample . A participant miss sample sample positive methamphetamine metabolite earn voucher . Accrued voucher never forfeit could redeem time study gift certificate good service promote healthy , pro-social behavior ; voucher could redeem cash .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Individual must identify male sex men ( MSM ) ; At least 18 year age ; HIV negative serostatus baseline rapid oral HIV antibody test ; Selfreported methamphetamine use within previous 72 hour test positive methamphetamine metabolite baseline ; Selfreported unprotected anal intercourse ( either receptive insertive ) HIVpositive status unknown partner within previous 3 month ; Selfreports previous hypersensitivity component Truvada ( tenofovir disoproxil fumarate emtricitabine ) ; Willing comply study requirement ( i.e. , monitor urine testing three time per week , meet physician within first week enrollment , begin medication immediately follow unexpected highrisk sexual exposure , contact clinic meet physician within 92 hour unexpected highrisk sexual exposure ) . Does identify male sex men ; Under 18 year age ; HIV positive , selfreport indicate result baseline rapid oral HIV antibody test ; Selfreports previous hypersensitivity component Truvada ; Has use methamphetamine previous 72 hour test positive methamphetamine metabolite ; Has unprotected anal intercourse HIVpositive status unknown partner within previous 3 month ; Unwilling comply study requirement .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>HIV</keyword>
	<keyword>Post-exposure prophylaxis</keyword>
	<keyword>HIV seronegativity</keyword>
</DOC>